Clinical Trials Browser

Phase 2 × tislelizumab × Breast × Clear all

NCT06538896 2024-11-26

Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT04914390 2024-01-22

NeoATCT

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT04734262 2023-11-18

SPARK

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05809895 2023-07-24

AdvanTIG-211

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT04501523 2023-02-21

Apollo

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT04913571 2021-06-04

TEMPLATE

Phase 2 Unknown

Triple Negative Breast Neoplasms